Credentials & Resume

I am an academic gastroenterologist with expertise in all aspects of digestive health and inflammatory bowel disease (IBD), supported by advanced fellowship training and a strong research background, including a PhD that has led to high-impact publications and presentations. I aspire to establish myself as a first-class clinician by integrating innovative translational research with exemplary, patient-centred, compassionate care.

• 2024

  Fellowship of The Royal Australasian College of Physicians (FRACP)

  Gastroenterology & Hepatology. Certified by CCRTGE for Gastroscopy & Colonoscopy.

• 2013 – 2017

  PhD — Inflammatory Bowel Disease and Colorectal Cancer

  St Mark's Hospital / Queen Mary University of London, UK.
  Winner of John Nicholls Prize for the Best Researcher of the Year (2015).

• 2005 – 2010

  Bachelor of Medicine, Bachelor of Surgery (MBBS)

  Imperial College London, UK.
  Merit in Clinical Pharmacology & Therapeutics.

• 2003 – 2004

  Master of Bioinformatics

  Imperial College London, UK.

• 2025 – current

  Staff Specialist Gastroenterologist & IBD Specialist

  St George Hospital, NSW, Australia.

• 2025 – 2026

  VMO Gastroenterologist

  Westmead Hospital, NSW, Australia.

• 2024

  Inflammatory Bowel Disease Fellow

  Concord Repatriation General Hospital, Sydney, Australia.
  Advanced IBD Fellowship.

• 2023

  Advanced Trainee in Gastroenterology

  Concord Repatriation General Hospital, Sydney, Australia.

• 2021 – 2022

  Advanced Trainee in Gastroenterology

  St George & Sutherland Hospitals, NSW, Australia.

• 2017 – 2020

  Basic Physician Trainee

  St George & Sutherland Hospitals, NSW, Australia.

• 2013 – 2016

  Clinical Research Fellow in Gastroenterology

  St Mark's Hospital, London, UK.
  A prestigious research fellowship at a world-renowned IBD unit.

• 2010 – 2012

  Internship & Residency

  Charing Cross & Northwick Park Hospital, London, UK.

To date, I have five first-author publications in high-impact Gastroenterology journals with >1,400 citations (IF = impact factor).

1. Wijnands AM, Penning De Vries B, Lutgens M, Al-Bakir, Bernstein C, CHR Choi, Coelho-Prabhu N, Colombel JF, Graham TA, Hart AL, Ten Hobe J, Itzkowitz S, Kirchgesner J, Mooiweer E, Shaffer S, Shah S, Elias S and Oldenburg B. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, Aug 2024; 22; 8: 1967-1708 (IF = 11.6)
2. Ding NS, Tassone D, Al-Bakir I, Wu K, Thompson A, Connell WR, Malietzis G, Lung P, Singh S, Choi RC, Gabe S, Jenkins J, Hart A. Systematic Review: The Impact and Importance of Body Composition in Inflammatory Bowel Disease. Journal of Crohn's Colitis, Sep 2022; 8;16 (9): 1475-1492 (IF = 9.1)
3. Curtius K, Kabir M, Al-Bakir I, Choi CH and et al. Multicentre derivation and validation of colitis-associated colorectal cancer risk prediction web tool. Gut, April 2022; 71 (4): 701-715 (IF = 23.1)
4. Yang DH, Park SJ, Kim HS…Kim HG and Choi CH, Korean Association for the Study of Intestinal Disease (KASID). High-definition Chromoendoscopy Versus High-definition White Light Colonoscopy for Neoplasia Surveillance in Ulcerative Colitis: A Multicenter Randomized Controlled Trial. American Journal of Gastroenterology, Oct 2019; 114-10; 1642-1648 (IF = 10.9)
5. Baker AM*, Cross W*, Curtius K*, Al Bakir I*, Choi CH* et al. Evolutionary History of Human Colitis-Associated Colorectal Cancer. Gut, June 2019; 68: 985-995 (*Joint first-authors; IF = 23.1, cited 192)
6. Choi CH, Al Bakir I, Ding NS et al. Cumulative Burden of Inflammation Predicts Colorectal Neoplasia Risk in Ulcerative Colitis. Gut, March 2019; 68: 414-422 (IF = 23.1, cited 206)
7. Choi CH, Al Bakir, Hart A, and Graham TG. Clonal Evolution of Colorectal Cancer in Inflammatory Bowel Disease. Nature Reviews Gastroenterology & Hepatology, Feb 2017; 14: 218-229 (IF = 46.8, cited 194)
8. Ding NS, Man YW, Choi CH et al. Endoscopic Dilatation of Crohn's Anastomotic Stricture is Effective in the Long-Term and Escalation of Medical Therapy Improves Outcomes in the Biologic Era. Journal of Crohn's and Colitis, Oct 2016; 10 (10): 1172-8 (IF = 9.1)
9. Choi CH, Rutter M, Askari et al. Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview. American Journal of Gastroenterology, July 2015; 110-7: 1022-34 (IF = 10.9, cited 347)
10. Choi CH, Ignatovic-Wilson A, Askari A et al. Low-grade Dysplasia in Ulcerative Colitis: Risk Factors for Progression to High-grade Dysplasia or Colorectal Cancer. American Journal of Gastroenterology, Oct 2015; 110-10: 1461-71 (IF = 10.9, cited 168)
11. Ayaru L, Ypsilantis P, Nanapragasam A, Choi CH et al. Prediction of Outcome in Acute Lower Gastrointestinal Bleeding Using Gradient Boosting. PLOS ONE, July 2015; 10-7: e0132485 (IF = 3.2)

Book Chapter

13. Choi CH and Al Bakir I. Ulcerative Colitis Surveillance. Biomarkers in Inflammatory Bowel Disease (edited by Ding NS and De Cruz P). Springer publishers, 2019 (ISBN 978-3-030-11446-6)

View Dr Choi's Publications in Google Scholar

I am an experienced presenter and have delivered 13 oral (including two invited and two plenary talks) and five poster presentations as a first author at major international conferences.

Invited Talks

1. Choi CH. IBD Surveillance — what is the current state of the art? National Inflammatory Bowel Disease Day, St Vincent Hospital, Melbourne, Australia, 2017 (Oral)
2. Choi CH. Colorectal Cancer Surveillance in Inflammatory Bowel Disease: The Past, Present and Future. Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, UK, 2016 (Oral)

Conferences

3. Choi CH, et al. The impact of female sex in persistence of advanced therapies in Crohn's disease and ulcerative colitis: Real-world data from Persistence Australian National Inflammatory Bowel Disease Cohort (PANIC) registry. Australian Gastroenterology Week (AGW), 2024 (Poster)
4. Choi CH, et al. TNF inhibitors have significantly poorer persistence in ulcerative colitis (UC) compared with Crohn's disease (CD), while vedolizumab persistence is poorer in advanced therapy (AT) exposed, but not AT-naïve CD patients compared with UC: data from Persistence Australian National Inflammatory Bowel Disease Cohort. AGW, Australia, 2024 (Poster)
5. Choi CH, I Al Bakir, NS Ding et al. Characterising and Using Inflammation Scores for Predicting Colorectal Neoplasia Risk in Ulcerative Colitis: A Large Cohort Study. British Society of Gastroenterology Annual Congress, Liverpool, UK, 2016 (Oral)
6. Choi CH, I Al Bakir, NS Ding et al. Risk Factors for Colorectal Neoplasia in Ulcerative Colitis: Results from the Largest and Longest-Running Colonoscopic Surveillance Program. Best abstract presentation, European Crohn's and Colitis Organisation (ECCO) congress, Amsterdam, Netherlands, 2016 (Plenary). Journal of Crohn's and Colitis 2016; 10 (suppl 1): S8
7. Choi CH, Warusavitarne J, Moorghen M et al. Whole Exome Sequencing Analysis of Colitis-associated Colorectal Cancer: Implications in Managing Colitis-associated Dysplasia. Frontiers in Intestinal and Colorectal Disease, London, UK, 2015 (Oral)
8. Choi CH, Ignatovic-Wilson A, Thomas-Gibson S et al. Low-grade Dysplasia in Ulcerative Colitis: Risk Factors for Progression to High-grade Dysplasia or Colorectal Cancer. Digestive Disease Federation congress, London, UK, 2015 (Oral). Gut 2015; 64: Suppl 1: A40
9. Choi CH, Rutter M, Askari A et al. Forty-year Analysis of Surveillance for Ulcerative Colitis Reveals Decreasing Risk of Interval and Advanced Cancer and Reducing Colectomy Rate for Dysplasia. Best abstract presentation, ECCO congress, Barcelona, Spain, 2015 (Plenary). Journal of Crohn's and Colitis 2015; 9 (suppl 1): S12
10. Choi CH, Rutter M, Askari A et al. Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: Chromoendoscopy and Over-Diagnosis. Digestive Diseases Week (DDW), Washington DC, USA, 2015 (Oral). Gastroenterology 04/2015; 148(4): S-160
11. Choi CH, Rutter M, Askari A et al. Forty-Year Analysis of Ulcerative Colitis Surveillance for Colorectal Cancer: Prevalence of Multifocal Neoplasia and Interval Cancer, Time-trend in Cancer Risk, and the Natural History of Progression of Each Grade of Dysplasia. United European Gastroenterology Week (UEGW), Vienna, Austria, 2014 (Oral). UEG Journal 2014; 2, (suppl 1): A70
12. Choi CH, Rutter M, Askari A et al. Long-Term Colonoscopic Surveillance for Ulcerative Colitis Reveals a Low Overall Rate of Cancer Progression and the Significant Risk of Cancer Following an "Indefinite for Dysplasia" Diagnosis. DDW, Chicago, USA, 2014 (Oral). Gastroenterology 2014; 146, Issue 5: S118
13. Choi CH, Ignatovic-Wilson A, Thomas-Gibson S et al. Endoscopic Resection of Dysplasia in Ulcerative Colitis: Long-term Outcome. ECCO congress, Copenhagen, Denmark, 2014 (Oral). Journal of Crohn's and Colitis 2014; 8 (Suppl 1): S61